Study for people with Liposarcoma

Recruiting Not a phased study

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Not a phased study
Sponsor Australia and New Zealand Sarcoma Association
Registry number NCT07377747
Started 5 September 2024 Today 16 October 2026 Estimated completion 1 December 2032

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Chris O'Brien Lifehouse Camperdown NSW Recruiting
Prince of Wales Hospital Randwick NSW Recruiting
Peter MacCallum Cancer Centre Melbourne VIC Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 100

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

1. Adult age ≥ 18 presenting with first recurrent well-differentiated and/or dedifferentiated liposarcoma of retroperitoneal space or pelvis after previous macroscopically complete resection (R0/R1 resection)

2. No distant metastasis on cross-sectional imaging of chest/abdomen/pelvis (CT and/or MRI) within 1 month to confirm the absence of metastatic disease

3. Previous histologically proven well-differentiated or dedifferentiated liposarcoma histology only

4. Sarcoma not originating from bone or abdominal or gynecological viscera

5. Tumor confirmed to be resectable with likely R0/R1 resection, and all disease must be deemed to be treatable by RT (joint decision by surgeon and radiation oncologist at a sarcoma multidisciplinary team meeting)

6. WHO performance status 0-2

7. American Society of Anaesthesiologist (ASA) score 1-3

8. No prior RT for the retroperitoneal liposarcoma

9. Prior systemic therapy is allowed

10. No concurrent active malignancy (except for low risk skin malignancy, low risk prostate carcinoma, low risk breast carcinoma including in situ disease)

11. Women of childbearing potential must have a negative pregnancy test within 3 weeks prior to the first day of study treatment

12. Patient deemed able to comply with study requirements according to investigator evaluation

13. Signed, IRB-approved written informed consent

Exclusion Criteria:

1. Unresectable disease or likely R2 resection as assessed by the multidisciplinary sarcoma team

2. Extent of recurrence where preoperative RT to all visible disease is not deemed to be feasible

3. Contradiction for RT such as history of bowel obstruction or mesenteric ischemia or severe chronic inflammatory bowel disease

4. Myxoid liposarcoma histology

5. Pregnancy

Dates on the record

Started 5 September 2024
Estimated completion 1 December 2032
Registry last updated 15 July 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 15 July 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.